Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.

SUMMARY In order to find the optimal dosage schedule of phenobarbitone for neonatal convulsions, four groups of patients were studied. Twelve infants (group 1) received a mean phenobarbitone dose of 9 5 mg/kg a day given intramuscularly for 3 days followed by 5-8 mg/kg a day given intramuscularly and then orally. Six infants (group 2) received a mean intravenous loading dose of 9 5 mg/kg followed by 6 8 mg/kg a day given intramuscularly or orally. Nine infants (group 3) received a mean loading dose of 14-9 mg/kg intravenously followed by a maintenance dose of 5 9 mg/kg a day. Thirteen patients (group 4) received a mean intramuscular loading dose of 15 2 mg/kg followed by 5 9 mg/kg a day. Blood samples were taken regularly and phenobarbitone levels were determined by gas liquid chromatography. A mean intravenous or intramuscular loading dose of 15 mg/kg of phenobarbitone safely achieved therapeutic levels within 2 hours of injection and high therapeutic levels were maintained with a dose of 6 mg/kg a day. Group 2. Six infants aged between 1 and 25 (mean 10-2) days and weighing between 1650 and 3580 (mean 3053) g received a mean loading dose of 9-5 mg/kg intravenously followed by a mean maintenance dose of 6-8 mg/kg a day given intramuscularly for at least the first 6 doses and then orally or intramuscularly. The first maintenance dose was given 12 hours after the end of the infusion. The aetiology of the seizures was: birth hypoxia 2; hydrocephalus and congenital heart disease 1; prematurity and intracranial haemorrhage 1; recurrent hypoxia due to tracheo-oesophageal fistula 1; idiopathic 1*.Group 3. Nine patients aged between 1 and 18 (mean 5-1) days and weighing between 1650 and 3980 (mean 3066) g received a mean loading dose of 14.9 mg/kg intravenously followed by a mean maintenance dose of 5-9 mg/kg a day given intramuscularly or orally in two divided doses. The aetiology of the seizures was: birth hypoxia 3; birth trauma and hypocalcaemia 2; congenital heart disease 2 (one with hypoparathyroidism and one with intracranial haemorrhage); intracranial haemorrhage 1; idiopathic 1*.Group 4. Thirteen patients aged between 1 and 22 (mean 5-5) days and weighing between 1520 and 4085 (mean 2891) g received a mean loading dose of 15*2 mg/kg given intramuscularly followed by a mean maintenance dose of 5.9 mg/kg a day given *Further clinical details are available on request.

No abstract

This report details a case of mucocutaneous lymph node syndrome (MLNS) recognized in the continental United States. Reported originally by Kawasaki in 1967,1 the syndrome has since occurred widely in Japan.2 Except for Melish et al.'s report of nine cases in Hawaii, MLNS has thus far not been reported from any other area.3 CASE REPORT T. S., a 2-year-old white boy, became ill with fever on August 19, 1974, and was examined on the third day of illness. His temperature had fluctuated between 38.9 and 39.4 C; when examined he had a markedly tender 2 x 4-cm single anterior cervical node accompanied by redness of the overlying skin.